5 completed, 2 unknown. 3 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 3 | Unknown 2, Completed 1 |
Follow Pharnext S.C.A.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (RS)-baclofen, naltrexone hydrochloride and D-sorbitol, Placebo - Charcot-Marie-Tooth Disease | Phase 3 | Unknown | Pharnext S.C.A. | 350 | 2021-03-30 | 2024-04-03 |
| The Impact of Charcot-Marie-Tooth Disease in the Real World Charcot-Marie-Tooth Disease | Completed | Vitaccess Ltd | 3321 | 2018-10-09 | 2024-11-14 | |
| Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A PXT3003 - Charcot-Marie-Tooth Disease, Type IA | Phase 3 | Unknown | Pharnext S.C.A. | 187 | 2017-03-07 | 2024-02-20 |
| Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT) PXT3003 dose 1, PXT3003 dose 2, placebo - Charcot-Marie-Tooth Disease Type 1A | Phase 3 | Completed | Pharnext S.C.A. | 323 | 2015-12-01 | 2020-02-27 |
| 24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion PXT00864 - Alzheimer Disease | Phase 2 | Completed | Pharnext S.C.A. | 45 | 2013-06-01 | 2016-02-15 |
| Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD) PXT00864, placebo - Alzheimer Disease | Phase 2 | Completed | Pharnext S.C.A. | 47 | 2013-02-01 | 2016-02-15 |
| Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A PXT3003 Low dose, PXT3003 Intermediate Dose, PXT3003 High Dose - Charcot-Marie-Tooth Disease, Hereditary Neuropathy With Liability to Pressure Palsies | Phase 2 | Completed | Pharnext S.C.A. | 80 | 2010-12-01 | 2017-11-22 |
Charcot-Marie-Tooth Disease (5) · Alzheimer Disease (2) · Peripheral Nervous System Diseases (2) · Genetic Diseases, Inborn (1) · Hereditary Sensory and Motor Neuropathy (1) · Tomaculous neuropathy (1)
Naltrexone (1) · Sorbitol (1)
France (6) · Belgium (3) · Canada (3) · Spain (3) · United Kingdom (3) · United States (3) · Germany (2) · Netherlands (2) · Denmark (1) · Israel (1) · Italy (1)
Jean-Marc Orgogozo, MD (2) · Mark Roberts, MD (2) · Shahram Attarian, MD (2) · Teresa Sevilla, MD (2) · Florian Thomas, MD (1) · Florian Thomas, MD PhD (1) · Jack Puymirat, MD (1) · Marianne De Visser, MD (1) · Marianne de Visser, MD (1) · Mario Saporta, MD (1) · Mark JW Larkin, PhD (1) · Peter Young, MD (1) · Philip Van Damme, MD (1) · Sharam Attarian, MD (1)
PMID 25519680, PMID 25491744, PMID 26070802, PMID 27387831, PMID 30650121, PMID 36005469
2015 (2)